Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine ( L antus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study-Reference-Cited by-同舟云学术

Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine ( L antus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

Published:2015-06-23 Issue:8 Volume:17 Page:726-733
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Blevins T. C.¹,Dahl D.²,Rosenstock J.³,Ilag L. L.⁴,Huster W. J.⁴,Zielonka J. S.⁴,Pollom R. K.⁴,Prince M. J.⁴

Affiliation:

1. Texas Diabetes & Endocrinology Austin TX USA

2. Gemeinschaftspraxis für Innere Medizin und Diabetologie Hamburg Germany

3. Dallas Diabetes and Endocrine Center at Medical City Dallas TX USA

4. Eli Lilly and Company Indianapolis IN USA

Funder

Eli Lilly and Company

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12496

Reference30 articles.

1. Human Insulin from Recombinant DNA Technology

2. The new world of biosimilars: what diabetologists need to know about biosimilar insulins

4. European Medicines Agency.Marvel Life‐Sciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel. EMEA/2435/2008. Press Release.2008. Available from URL:www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015335.pdf. Accessed 15 October 2014.

5. European Medicines Agency.Marvel Life Sciences Ltd withdraws its marketing authorisation applications for Solumarv Isomarv medium and Combimarv (human insulin). Press Release.2012. Available from URL:http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/11/WC500135156.pdf. Accessed 15 October 2014.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuevas Insulinas en el tratamiento de la Diabetes Tipo 1;Andes Pediatrica;2023-06-15

2. The use of biosimilar insulins in 2023;Canadian Diabetes & Endocrinology Today;2023-03-20

3. An Institutional Guide for Formulary Decisions of Biosimilars;Hospital Pharmacy;2022-11-29

4. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary;Clinical Pharmacology & Therapeutics;2022-11-04

5. Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials;Journal of Diabetes Science and Technology;2022-07-11